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The Editorial on the Research Topic
Recent Advances inVoltage-Gated SodiumChannels, their Pharmacology andRelatedDiseases
After the success of the first Research Topic on voltage-gated sodium channels (Desaphy and
Chahine), we were encouraged to re-open the topic for submission. In this second issue, we publish
new insights in VGSC gatingmechanisms, the role of β1-subunit, the involvement of VGSC in pain,
encephalopathy, and cancer, and the molecular mechanism of VGSC drugs.
In humans, nine genes encode VGSC α-subunits that are responsible for ion permeation
and voltage-dependent gating (Chahine et al., 2008; Savio-Galimberti et al.). The α-subunits
are composed of four homologous domains (DI–DIV), each with six α-helical transmembrane
segments (S1–S6). Residues of the S6 segments are thought to line the internal pore vestibule and
contribute to the binding site for local anesthetics (LA) and antiarrhythmic drugs. Although the
concept of state-dependent drug binding is well accepted, the underlying molecular mechanism
is not well understood. The prevailing view is that conformational changes in the binding site
associated with the voltage-dependent activation and inactivation of channels enhance drug
binding and stabilize channels in non-conducting states. To assess the aqueous accessibility of
DIVS6, O’Leary and Chahine introduced cysteine residues in the cardiac Nav1.5 channel and
examined their sensitivity to MTSET, a thiol-specific reagent (O’Leary and Chahine). The MTSET
inhibition of these cysteine mutants was well-correlated with the steady-state availability of the
MTSET-modified channels, suggesting a link between fast inactivation and MTSET inhibition.
MTSETmodification of I1770Cmutant disrupted fast inactivation, in agreement with the suggested
contribution of the intracellular end of DIVS6 to the inactivation gate binding site. These data
indicate that the docking of the inactivation gate induces a localized conformational change that
regulates the aqueous accessibility of residues situated near the C-terminus of DIVS6.
Four accessory β-subunits (β1–β4) can complex with the α-subunit (Brackenbury and Isom;
Chahine and O’Leary). The β-subunits have a single membrane-spanning α-helix with a large
extracellular N-terminal domain incorporating an immunoglobulin-like fold resembling cell
adhesion molecules. Thus it was proposed that, besides the modulation of α-subunits, β-subunits
may participate in cell–cell and cell–matrix adhesion. Baroni andMoran reviewed the neuronal and
cardiac channelopathies caused by β1-subunit mutations, which the high interindividual variability
of symptoms and the underlying molecular mechanisms are not yet fully understood (Baroni and
Moran).
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The VGSC α-subunits and partner proteins are also
modulated by post-translational modifications including
phosphorylation, glycosylation, ubiquitination, and
methylglyoxal-mediated glycation (Laedermann et al.). These
mechanisms and their role in inherited and acquired pain
syndromes are discussed by Laedermann and collaborators,
which may open new avenues in the development of analgesics.
Inherited pain syndromes associated with Nav1.7, Nav1.8, and
Nav1.9 mutations, are only a few of the many human sodium
channelopathies. Mutations of Nav1.4 cause skeletal muscle
disorders; Nav1.5 is responsible for genetic heart diseases; and
mutations in Nav1.1 and Nav1.2 are responsible for a spectrum
of epileptic syndromes. In their review, Wagnon and Meisler
describe how the recent use of exome sequencing in patients
with early-onset epileptic encephalopathy have permitted the
identification of de novo mutations of Nav1.6 causing this non-
familial disorder (Wagnon and Meisler). The first functional
studies of Nav1.6 mutants suggest either a gain or a loss of
channel function, so further studies are needed to complete our
understanding of the pathological mechanisms and to identify
the best treatment.
Besides their canonical role in excitable cells, the expression
of VGSC in non-excitable tissues calls our attention to other
possible function. The last two decades have shown an increasing
number of studies reporting the abnormal expression of VGSC
in cancer cells. Roger and collaborators summarize these
studies, highlighting the possible critical role of VGSC in
promoting cell migration and invasiveness (Roger et al.). VGSC
may thus appear as promising druggable targets in cancer.
Martin and collaborators provide us with a systematic review
of studies testing the effects of sodium channel blockers in
breast, colorectal, and prostate cancer (Martin et al.). Although
preclinical studies suggest some benefits of these drugs in
inhibiting cancer progression, there is still little information
regarding their therapeutic value in humans. The authors claimed
the need for a standardization of future studies and outcome
measures to address this important issue.
The available VGSC blockers are used as anticonvulsants,
antiarrhythmics, analgesics, neuroprotectants, and
antimyotonics (Camerino et al., 2008). Most of these drugs
show overlapping molecular mechanisms and little selectivity
among VGSC isoforms. Their therapeutic index is mainly
determined by their preferential binding to open/inactivated
channels, allowing a selective action in pathological overexcited
tissues (Fozzard et al.). Several drugs used for other indications
are also able to potently inhibit VGSC. Lazar and collaborators
investigated the different pH sensitivity of many of these
VGSC inhibitors, refining our current conception of the role
of alkalization in drug potency (Lazar et al.). In agreement
with a previous study (Morris et al.), they propose a major role
of ligand-membrane interactions in determining potency and
selectivity of sodium channel blockers.
If, on the one hand, the “promiscuous” inhibition of
VGSC by drugs known to primarily target other proteins
may question their safe use, on the other, it was proposed
that such activity may contribute to the therapeutic efficacy
of some drugs. For instance, many analgesics inhibit VGSC
at clinical concentrations, including tricyclic antidepressants
and some opioids. In this topic, Carbonara and collaborators
report the effects of new sumatriptan bioisosteres on neuronal
Nav1.7 channels, a main contributor to pain transmission
(Carbonara et al.). They identified new VGSC blockers with
mixed serotoninergic 5HT1D receptor agonism, which could
represent interesting lead compounds for the synthesis of new
anti-hyperalgesic drugs.
Altogether, these publications demonstrate that VGSC are
still surfing on the crest of a wave with many current studies
dealing with their intimate molecular gating mechanisms, their
modulation by cell signaling processes, the genotype/phenotype
relationship in sodium channelopathies, the exploration of novel
function in non-excitable cells, and the search for new drugs.
We are confident that new important VGSC findings will be
published in a next future. Will this prompt us to re-open the
topic again?
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